Clinical Trials
3
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
- First Posted Date
- 2024-12-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Zhuhai Yufan Biotechnologies Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06727630
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorAdvanced Solid Malignancies
- Interventions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Zhuhai Yufan Biotechnologies Co., Ltd
- Target Recruit Count
- 267
- Registration Number
- NCT05315167
- Locations
- 🇨🇳
The first affiliated hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳Cancer hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid TumorAdvanced Solid Malignancies
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Zhuhai Yufan Biotechnologies Co., Ltd
- Target Recruit Count
- 39
- Registration Number
- NCT05159700
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida, United States
🇺🇸Christ Hospital, Cincinnati, Ohio, United States
News
No news found